Specify the programme decision
Connect the biological endpoint to a defined stage, therapeutic question and action.
For pharma, biotech and CRO teams
Develop models around the decision they must support.
JetBio works from a defined drug-development question towards a fit-for-purpose 3D model and reproducible workflow. The route begins with context, acceptance criteria and operational fit, not a generic printer demonstration.
A decision-led starting point
Define the context before developing the model.
The same model cannot answer every discovery, efficacy or safety question. A credible programme states where the model will be used, what it will measure and what decision its output may inform.
Design for human relevance
Select cells, materials, architecture and culture conditions around the biology that matters.
Plan for repeatable use
Include operators, formats, throughput, controls, readouts and transfer requirements in the development brief.
Applications-led modularity
Use the print mode the biology requires.
Reactive jet impingement, microvalve and inkjet development modes offer different routes for placing cells and materials. A project may use one mode or combine complementary capabilities, subject to material compatibility and the required model architecture.
Disease modellingAssay developmentSelected safety researchMultiwell workflows
Explore the platform Evidence requirements
Build towards adoption, not a one-off demonstration.
Define during scoping
- Biological question and intended decision
- Reference method, controls and comparator
- Required format, throughput and readout
- Acceptance criteria and evidence threshold
- IP, confidentiality and data responsibilities
Test during development
- Model performance and biological relevance
- Within-run and between-run reproducibility
- Operator, equipment and workflow robustness
- Scalability and transfer across the intended setting
- Support, training and change-control needs
The ABPI and NC3Rs identify robustness, validation, standardisation and scalability as central gaps between promising academic models and routine pharmaceutical use. JetBio does not represent research deployments as qualified drug-development tools.
Read the ABPI and NC3Rs landscape reviewCommercial pathway
De-risk the application before procurement.
- 01
Confidential discovery
Align on therapeutic area, programme stage, current model and decision need.
- 02
Feasibility brief
Define materials, format, comparator, controls, evidence gates, responsibilities and commercial terms.
- 03
Application project
Generate relevant evidence against a bounded work package and record limitations as well as results.
- 04
Adoption decision
Review the evidence, operational fit, support model and next procurement or co-development step.
Frequently asked questions
Questions drug-development teams ask first.
Where could JetBio fit in a drug-discovery workflow?
Potential uses include disease-model development, target and mechanism research, assay development and selected safety or efficacy studies. The relevant use must be defined for each programme rather than assumed from the technology alone.
Does JetBio claim that its models replace animal studies?
No. Human-relevant in vitro models may reduce or replace animal use in defined contexts, but that requires suitable evidence, validation and, where applicable, regulatory engagement. JetBio does not make a blanket replacement claim.
Can JetBio support throughput and multiwell formats?
Selected multiwell workflows form part of the development pathway. Required plate format, replicate number, handling, readout and automation interfaces must be assessed during scoping.
What is the first commercial step?
The usual starting point is a confidential fit discussion followed, where appropriate, by a scoped feasibility or application-development project with agreed evidence gates.
Enquiry form
Define the drug-development question.
Share the context of use, current model, readout, format, throughput and evidence threshold for a confidential fit review.
Please do not include confidential, personal health or unpublished research data.
Start a useful conversation
Review the platform and current evidence.
Examine the modular architecture and the boundary between demonstrated research and commercial proof in progress.